|
Market Closed -
NYSE
16:10:00 2026-10-29 EDT
|
5-day change | 1st Jan Change | ||
| 0.5401 USD | +3.25% |
|
-0.72% | -89.13% |
| 10-06 | Kairos Pharma, Ltd. Reports Positive Interim Efficacy Data From Phase 2 Trial Of ENV-105 In Metastatic Prostate Cancer | CI |
| 08-21 | Kairos Pharma to Conduct 1-for-7 Reverse Stock Split | MT |
| Market Cap | 1.83M 1.64M 1.51M 1.37M 2.56M 174M 2.6M 18.03M 7.19M 91.12M 6.86M 6.72M 289M | P/E 2026 * |
-0.23x | P/E 2027 * | -0.15x |
|---|---|---|---|---|---|
| Enterprise Value | 1.83M 1.64M 1.51M 1.37M 2.56M 174M 2.6M 18.03M 7.19M 91.12M 6.86M 6.72M 289M | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
66.39% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| KAPA | Delayed | |
CBOE
| KAPA | Real-time |
| 1 day | +3.25% | ||
| 1 week | -0.72% | ||
| Current month | -67.07% | ||
| 1 month | -67.46% | ||
| 3 months | -74.20% | ||
| 6 months | -86.02% | ||
| Current year | -89.13% |
| 1 week | 0.52 |  | 0.58 |
| 1 month | 0.52 | | 2.16 |
| Current year | 0.52 | | 7.28 |
| 1 year | 0.52 | | 7.91 |
| 3 years | 0.52 | | 28 |
| 5 years | 0.52 | | 28 |
| 10 years | 0.52 | | 28 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Yu
CEO | Chief Executive Officer | 61 | 2013-06-16 |
Doug Samuelson
DFI | Director of Finance/CFO | 66 | 2018-12-31 |
| Chief Tech/Sci/R&D Officer | 66 | - |
| Director | Title | Age | Since |
|---|---|---|---|
John Yu
CHM | Chairman | 61 | 2013-06-16 |
Hyun Bae
BRD | Director/Board Member | 56 | 2020-09-08 |
Han-Soo Keyoung
BRD | Director/Board Member | 51 | 2024-09-10 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/8/25 | Free | Chief Financial Officer | 152,672 | 0.7360% | ||
| 10/8/25 | Free | Chief Executive Officer | 190,840 | 0.9200% | ||
| 10/8/25 | Free | Director | 19,084 | 0.0920% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.25% | -0.72% | -92.99% | - | 1.83M | |
| +0.34% | +1.12% | +34.75% | +61.06% | 64.38B | |
| -0.32% | +2.48% | +14.12% | +83.26% | 56.16B | |
| +1.22% | +2.53% | +16.01% | +107.96% | 54.16B | |
| -1.43% | -1.17% | +26.27% | +52.86% | 45.33B | |
| -0.48% | -2.80% | +18.01% | +117.99% | 42.25B | |
| +0.82% | +1.37% | +227.94% | +922.41% | 40.78B | |
| +0.62% | +43.72% | +106.58% | +90.86% | 33.8B | |
| -0.26% | -2.57% | +12.55% | +45.18% | 32.25B | |
| -1.29% | -2.88% | +21.60% | -11.92% | 23.57B | |
| Average | +0.41% | +3.98% | +38.48% | +163.30% | 39.27B | |
| Weighted average by Cap. | +0.19% | +3.60% | +50.07% | +162.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -7.94M -7.11M -6.56M -5.94M -11.11M -756M -11.28M -78.3M -31.24M -396M -29.81M -29.17M -1.25B | -14.16M -12.68M -11.7M -10.59M -19.8M -1.35B -20.12M -140M -55.7M -706M -53.15M -52.02M -2.24B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-29 | US$0.5401 | +3.25% | 123,037 |
| 26-10-28 | US$0.5231 | -1.30% | 64,963 |
| 26-10-27 | US$0.5300 | -1.14% | 33,967 |
| 26-10-26 | US$0.5361 | -4.01% | 66,503 |
| 26-10-23 | US$0.5585 | +2.67% | 112,891 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- KAPA Stock
Select your edition
All financial news and data tailored to specific country editions
